Race, common genetic variation, and therapeutic response disparities in heart failure

JACC: Heart Failure

Volumn 2, Issue 6, 2014, Pages 561-572

  Taylor, Mathew R ^a   Sun, Albert Y ^b   Davis, Gordon ^c   Fiuzat, Mona ^b   Liggett, Stephen B ^d   Bristow, Michael R ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ARCA biopharma   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Genetic polymorphisms; Heart failure; Pharmacogenetics; Racial ancestry

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; MINERALOCORTICOID ANTAGONIST; PLACEBO; THREONINE; ADRENERGIC RECEPTOR;

ANCESTRY GROUP; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CAUCASIAN; CELL PROTECTION; CYTOPATHOGENIC EFFECT; DEVICE THERAPY; DNA POLYMORPHISM; DRUG RESPONSE; EAST AFRICAN; EXON; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOME SIZE; GENOTYPE; HAPLOTYPE; HEART FAILURE; HEART VENTRICLE REMODELING; HOMOZYGOSITY; HUMAN; HUMAN GENOME; NONHUMAN; OBSERVATIONAL STUDY; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN COLOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; GENETICS; MORTALITY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CONTINENTAL POPULATION GROUPS; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HEART FAILURE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84959935662     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.06.010     Document Type: Review

References (43)

1. Spear B.B., Heath-Chiozzi M., Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001, 7:201-204.
2. Johnson J.A. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation 2008, 118:1383-1393.
3. Bristow M.R. Pharmacogenetic targeting of drugs for heart failure. Pharmacol Ther 2012, 134:107-115.
4. Twyman R. Mutation or polymorphism? Wellcome Trust, The Human Genome website. Available at: . Accessed April 18,2014. http://genome.wellcome.ac.uk/doc_WTD020780.html.
5. Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. National Academies Press: Washington, DC,2003.
6. Tishkoff S.A., Kidd K.K. Implications of biogeography of human populations for "race" and medicine. Nat Genet 2004, 36:S21-S27.
7. Li W.H., Sadler L.A. Low nucleotide diversity in man. Genetics 1991, 129:513-523.
8. Sachidanandam R., Weissman D., Schmidt S.C., et al. Amap of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 15;409:928-33.
9. Abecasis G.R., Altshuler D., et al. Amap of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073. 1000 Genomes Project Consortium.
10. Tishkoff S.A., Verrelli B.C. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet 2003, 4:293-340.
11. Gabriel S.B., Schaffner S.F., Nguyen H., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
12. Jorde L.B., Wooding S.P. Genetic variation, classification and "race.". Nat Genet 2004, 36:S28-S33.
13. Rosenberg N.A., Pritchard J.K., Weber J.L., et al. Genetic structure of human populations. Science 2002, 298:2381-2385.
14. Ioannidis J.P., Ntzani E.E., Trikalinos T.A. "Racial" differences in genetic effects for complex diseases. Nat Genet 2004, 36:1312-1318.
15. Bristow M.R. Treatment of chronic heart failurewith β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011, 109:1176-1194.
16. A haplotype map of the human genome. Nature 2005, 437:1299-1320. International HapMap Consortium.
17. Taylor M.R., Bristow M.R. The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail 2004, 10:281-288.
18. Siu H., Jin L., Xiong M. Manifold learning for human population structure studies. PLoS One 2012, 7:e29901.
19. Raynolds M.V., Bristow M.R., Bush E.W., et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993, 342:1073-1075.
20. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. NEngl J Med 2002, 347:1135-1142.
21. Covolo L., Gelatti U., Metra M., et al. Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. Biomarkers 2003, 8:429-436.
22. Metra M., Zani C., Covolo L., et al. Role of beta1- and alpha2C-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. Eur J Heart Fail 2006, 8:131-135.
23. Canham R.M., Das S.R., Leonard D., et al. Alpha2cDel322-325 and beta1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume. JAm Coll Cardiol 2007, 49:274-277.
24. Yang J., Zhao Y., Hao P., et al. Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk. PLoS One 2013, 8:e63309.
25. Kitsios G., Zintzaras E. Genetic variation associated with ischemic heart failure: a HuGE review and meta-analysis. Am J Epidemiol 2007, 166:619-633.
26. Liggett S.B., Cresci S., Kelly R.J., et al. AGRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14:510-517.
27. Lanfear D.E., Hrobowski T.N., Peterson E.L., et al. Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail 2012, 5:202-208.
28. Sehnert A.J., Daniels S.E., Elashoff M., et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. JAm Coll Cardiol 2008, 52:644-651.
29. Fiuzat M., Neely M.L., Starr A.Z., Kraus W.E., Felker G.M., Donahue M., Adams K., Piña I.L., Whellan D., O'Connor C.M. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail 2013, 15:258-266.
30. Anderson J.L., Krause-Steinrauf H., Goldman S., et al. Failure of benefit and early hazard of bucindolol for class IV heart failure. JCard Fail 2003, 9:266-277.
31. Pereira S.B., Velloso M.W., Chermont S., et al. β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Mol Med Rep 2013, 7:259-265.
32. Magnusson Y., Levin M.C., Eggertsen R., et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005, 78:221-231.
33. Green S.A., Turki J., Innis M., Liggett S.B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994, 33:9414-9419.
34. Bristow M.R., Krause-Steinrauf H., Nuzzo R., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004, 110:1437-1442.
35. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEngl J Med 2004, 351:2049-2057.
36. Davies E., Holloway C.D., Ingram M.C., et al. Aldosterone excretion rate and blood pressurein essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999, 33:703-707.
37. Brand E., Chatelain N., Paillard F., et al. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur J Hum Genet 2002, 10:715-723.
38. Danser A.H., Schalekamp M.A., Bax W.A., et al. Angiotensin-converting enzyme in the human heart.Effect of the deletion/insertion polymorphism. Circulation 1995, 92:1387-1388.
39. Martin M.M., Buckenberger J.A., Jiang J., et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. JBiol Chem 2007, 282:24262-24269.
40. van Leeuwen N., Bellingrath S., de Kloet E.R., et al. Human mineralocorticoid receptor (MR) gene haplotypes modulate MR expression and transactivation: implication for the stress response. Psychoneuroendocrinology 2011, 36:699-709.
41. Armstrong D., Wing S., Tyroler H.A. Race differences in estimates of sudden coronary heart disease mortality, 1980-1988: the impact of ill-defined death. JClin Epidemiol 1996, 49:1247-1251.
42. Splawski I., Timothy K.W., Tateyama M., et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002, 297:1333-1336.
43. eEnsemble east. CCDS: the CCDS database.Available at: . Accessed September 18,2014. http://www.ensembl.org/info/genome/genebuild/ccds.html.